Arcturus BioCloud is a technology company.
Arcturus BioCloud has raised $100K across 1 funding round.
Arcturus BioCloud has raised $100K in total across 1 funding round.
Arcturus BioCloud has raised $100K in total across 1 funding round.
Arcturus BioCloud's investors include Babel Ventures.
Arcturus BioCloud is a virtual bio-foundry that provides a user-friendly, cloud-based platform as a service (PaaS) for rapid prototyping and genetic engineering of microorganisms[1][2][3][4][7]. It enables users to outsource and accelerate experiments in synthetic biology, simplifying the development of innovative biotech products for researchers, startups, and companies in the bioengineering space[1][4]. The platform serves biotech innovators by solving the challenges of traditional lab-based genetic engineering, such as high costs, slow iteration, and access to specialized equipment, through an online interface that democratizes rapid prototyping[2][3][7].
Founded in 2014, Arcturus BioCloud emerged to rethink genetic engineering for microbes, introducing a "lab in the cloud" model that shifts experiments from physical labs to a virtual platform[3][7]. While specific founders are not detailed in available sources, the company was driven by the need to streamline outsourcing of bio-experiments, with its current CEO leading operations as of recent records[3][4]. Early traction focused on creating an intuitive online interface for microorganism engineering, positioning it as a pioneer in accessible synthetic biology tools[2][7].
*Note: Some sources conflict on scope—one outlier describes transportation tech, but consensus across multiple directories confirms biotech focus[1][2][3][4][5][7].*
Arcturus BioCloud rides the synthetic biology wave, where cloud platforms are transforming biotech R&D amid rising demand for scalable genetic engineering[1][2][3][7]. Timing aligns with advances in cloud computing and automation, enabling faster microbe prototyping critical for applications like biofuels, pharmaceuticals, and sustainable materials. Market forces favoring remote, cost-effective bio-tools—driven by post-pandemic lab constraints and startup growth—position it well in the $10B+ synbio market. It influences the ecosystem by lowering entry barriers, fostering innovation among indie researchers and accelerating startup timelines in bio-foundry tech[4][7].
Arcturus BioCloud is poised to expand as AI-driven design tools and automated labs converge with its cloud platform, potentially integrating predictive modeling for microbe engineering. Trends like decentralized bio-manufacturing and climate-focused synbio will shape its path, with opportunities in partnerships for industrial-scale applications. Its influence may grow by powering the next wave of bio-innovators, evolving from prototyping niche to foundational infrastructure in virtual biotech—building on its early vision of cloud-accessible genetic engineering[1][3][7].
Arcturus BioCloud has raised $100K across 1 funding round. Most recently, it raised $100K Seed in February 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2015 | $100K Seed | Babel Ventures |